A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Paricalcitol (Zemplar)

Vitamin D2 Analog class · 10 generic manufacturers · 32 ANDAs filed at FDA.

First FDA approval1998-04-17
Generic availableYes · 10 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$4.5M in CY2024 Part D spend42K claims · 12K beneficiaries · 329 plans surveyed

Lowest NADAC
$1.06/unit
6 NDCs benchmarked, lowest of all strengths.
Average NADAC
$1.46
Across all dosage forms in distribution.
Highest NADAC
$1.86
Range is tight.
Plans with PA
252 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Paricalcitol used for?

Paricalcitol is a Vitamin D2 Analog medication tracked in Medicare Part D.

Is there a generic for Paricalcitol?

Yes. 32 ANDAs filed at FDA, 10 generic manufacturers currently shipping.

How much does my plan pay for Paricalcitol?

Across 329 Part D plans, Paricalcitol averages $1.46/unit (NADAC). Lowest available: $1.06/unit. Highest in distribution: $1.86/unit.

Is Paricalcitol on the FDA shortage list?

Paricalcitol has been discontinued by its manufacturer(s).

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Vitamin D2 Analog1 alternative in D1
01
Doxercalciferol
Vitamin D2 Analog
Lowest NADAC
9Generic mfrs
$902,583CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (6 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.